We have located links that may give you full text access.
Journal Article
Review
Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas.
Lymphoma is a heterogeneous group of diseases with many curable subtypes. Primary treatment cures a significant proportion of, but not all, patients. Patients not achieving a complete remission with primary treatment, or those who relapse later, have a second chance of cure with high-dose chemotherapy and haematopoietic stem cell transplantation. Response assessment is therefore crucial in the management of lymphomas. FDG-PET has an emerging role in assessing response, both at the end of and during treatment. This article will review the current published evidence and offer some suggestions on future directions from a clinician's viewpoint.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app